SCHEMBL4764299

SCHEMBL4764299

COc1ccc(Nc2ncnc3[nH]c(-c4ccc(CN5CCOCC5)cc4)cc23)cn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 5/20 0.61
CDK2 P24941 2/20 0.53
CDK1 P06493 1/20 0.53
CASP3 P42574 1/20 0.53
CDK9 P50750 1/20 0.53
CASP7 P55210 1/20 0.53
PIK3CD O00329 3/20 0.52
PIK3CA P42336 3/20 0.52
PIK3CB P42338 3/20 0.52
PIK3CG P48736 3/20 0.52
RET P07949 3/20 0.47
EGFR P00533 2/20 0.47
STK10 O94804 1/20 0.47
MAP4K4 O95819 1/20 0.47
ABL1 P00519 1/20 0.47
ERBB2 P04626 1/20 0.47
YES1 P07947 1/20 0.47
PDGFRB P09619 1/20 0.47
BCR P11274 1/20 0.47
FLT1 P17948 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4764512 0.90 PIK3CA (0.51) CSF1RPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4770678 0.90 KDR (0.59) CSF1RPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4766414 0.88 CSF1R (0.64) CSF1RCDK2CDK1CASP3CDK9
SCHEMBL4766961 0.88 CSF1R (0.61) CSF1RCDK2CDK1CASP3CDK9
SCHEMBL4766666 0.85 CSF1R (0.59) CSF1RCDK2CDK1CASP3CDK9
SCHEMBL4764504 0.81 RET (0.49) CSF1RPIK3CGRETEGFRKIT
SCHEMBL4763944 0.81 CSF1R (0.63) CSF1RCDK2CDK1CASP3CDK9
SCHEMBL4766876 0.81 CSF1R (0.63) CSF1RCDK2CDK1CASP3CDK9
SCHEMBL4763961 0.81 CSF1R (0.63) CSF1RRETEGFRSTK10MAP4K4
SCHEMBL4774356 0.80 CSF1R (0.65) CSF1RCDK2CDK1CASP3CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1416935-B1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2008-03-12 EP claimed
US-7244729-B2 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2007-07-17 US claimed
US-20040248911-A1 7H-pyrrolo[2,3-d]pyrimidine derivatives BOLD GUIDO (CH) 2004-12-09 US claimed
US-20040242600-A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2004-12-02 US claimed
US-7390805-B2 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2008-06-24 US disclosed
EP-1416935-B1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2008-03-12 EP disclosed
US-7323469-B2 7H-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2008-01-29 US disclosed
US-7244729-B2 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2007-07-17 US disclosed
US-20070161632-A1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES BOLD GUIDO 2007-07-12 US disclosed
US-20040242600-A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161632-A1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES TYMP, DPYD, CCND2 CSF1R 4089/4885CDK2 16/4885CDK1 99/4885
US-20040248911-A1 7H-pyrrolo[2,3-d]pyrimidine derivatives DPYD, DHPS, TYMP CSF1R 3024/4885CDK2 84/4885CDK1 256/4885
US-20040242600-A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives DPYD, TYMP, TYMS CSF1R 3516/4885CDK2 35/4885CDK1 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.